Thursday, 18 Jan 2018

You are here

Obesity Associated with Late-Onset Psoriatic Arthritis

A recent study reports that obesity is linked to late-onset psoriasis and psoriatic arthritis (PsA).  By contrast being of normal weight may be associated with an earlier onset of the disease adn HLA-B27.

Patients with early PsA were compared to those without arthritis (PsC), with regard to their body mass index (BMI) and HLA risk alleles for psoriatic disease (HLA-B*27, B*3901, B*3801, B*0801, B*4402, B*4403, and C*0602). A case-controlled designed was utilized to detect associations. 

Obesity was more common among the 314 patients with early PsA compared to 498 PsC patients (OR 1.77; p = 0.002).

Higher BMI was significantly associated with older age at onset for both PsA and psoriasis (p =  0.009).

HLA-B*27 was higher in patients with normal weight compared with those with higher BMI (p = 0.002).

Body weight significantly influences the onset and expression of psoriatic disease.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Salt Drives Gut-Brain Connection via IL-17

A study from Nature Neuroscience shows that a high salt diet may mediate neurovascular disease by altering microbiome and the expansion of TH17 cells in the small intestine, thereby increasing plasma interleukin-17 (IL-17) and its subsequent effects on endothelium in the brain.

MEASURE 3 Study - Anti-IL17 Benefits Persist in Spine Disease

Patients with ankylosing spondylitis (AS) have shown rapid and sustained responses to secukinumab (Cosentyx) in a third phase III trial that includes a higher dose of this anti-interleukin-17A monoclonal antibody, researchers reported.

Therapeutic Update: 5 Questions on FDA Hearing for Tofacitinib in PsA (Best of 2017)

In this Therapeutic Update, Drs. Mease, Gibofsky and Cush answer five questions regarding the August 3rd FDA Arthritis Advisory Committee meeting that reviewed the potential approval of tofacitinib (Xeljanz) in patients with active psoriatic arthritis. The panel was nearly unanimous (10-1) in favor of the efficacy and safety profile of of tofacitinib, and similarly voted 10-1 to approve this drug for use in PsA. Final decisions on these recommendations from the AAC panel will be made at a later date by the FDA. 

Cardiac Disturbances Increased in Spondyloarthritis

A prospective Swedish study between 2001–2009 found a higher risk of aortic regurgitation, pacemaker, AV block and atrial fibrillation in SpA, AS, uSpA and PsA patients.

FDA Approves Xeljanz for Use in Psoriatic Arthritis

Pfizer Inc. announced today that the United States Food and Drug Administration (FDA) has approved Xeljanz (tofacitinibi) for the treatment of adult patients with active psoriatic arthritis (PsA) who have had an inadequate response or intolerance to methotrexate or other disease-modifying antirheumatic drugs (DMARDs).